Data-quality flags on Colombia
People newly enrolled on ART during the year, 2023 (PEPFAR Panorama Spotlight). The value moved from 537 in 2022 to 1,769 in 2023, a change of more than threefold in a single year. The move from 537 to 1,769 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
HIV tests performed with the result returned to the person, 2023 (PEPFAR Panorama Spotlight). The value moved from 7,695 in 2022 to 32,833 in 2023, a change of more than threefold in a single year. The move from 7,695 to 32,833 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS), 2023 (PEPFAR Panorama Spotlight). The value moved from 419 in 2022 to 1,982 in 2023, a change of more than threefold in a single year. The move from 419 to 1,982 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Number of people on ART (PEPFAR MER TX_CURR), 2023 (PEPFAR Panorama Spotlight). The value moved from 861 in 2022 to 3,912 in 2023, a change of more than threefold in a single year. The move from 861 to 3,912 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Number of people on ART (PEPFAR MER TX_CURR), 2025 (PEPFAR Panorama Spotlight). The value moved from 4,331 in 2024 to 1,306 in 2025, a change of more than threefold in a single year. The move from 4,331 to 1,306 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2024 and 2025 are not comparable. Check the figures by reporting organisation before reading a trend across 2024 and 2025.
People receiving PrEP, 2024 (PEPFAR Panorama Spotlight). The value moved from 134 in 2023 to 1,147 in 2024, a change of more than threefold in a single year. The move from 134 to 1,147 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2023 and 2024 are not comparable. Check the figures by reporting organisation before reading a trend across 2023 and 2024.
Number of PLHIV virally suppressed (VL<1000), 2023 (PEPFAR Panorama Spotlight). The value moved from 378 in 2022 to 2,749 in 2023, a change of more than threefold in a single year. The move from 378 to 2,749 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Number of PLHIV virally suppressed (VL<1000), 2025 (PEPFAR Panorama Spotlight). The value moved from 3,093 in 2024 to 796 in 2025, a change of more than threefold in a single year. The move from 3,093 to 796 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2024 and 2025 are not comparable. Check the figures by reporting organisation before reading a trend across 2024 and 2025.
Sources of the figures for Colombia
| Source | Type | Rows | Indicators | Years | Read from | Retrieved |
|---|---|---|---|---|---|---|
| UNICEF HIV/AIDS dataset | Modelled estimate | 1,374 | 5 | 2010–2025 | sdmx.data.unicef.org | 2026-10-20 |
| UNAIDS AIDSinfo | Modelled estimate | 808 | 30 | 2000–2024 | aidsinfo.unaids.org | 2026-10-20 |
| Demographic and Health Surveys | Survey | 281 | 3 | 2000–2015 | api.dhsprogram.com | 2026-10-16 |
| WHO Global Health Observatory | Modelled estimate | 262 | 12 | 2000–2025 | ghoapi.azureedge.net | 2026-10-12 |
| WHO Global Tuberculosis Programme | Programme record | 181 | 17 | 2000–2025 | extranet.who.int | 2026-10-16 |
| IATI, through d-portal | Expenditure account | 57 | 3 | 2000–2026 | d-portal.org | 2026-10-12 |
| OECD Creditor Reporting System | Expenditure account | 55 | 3 | 2002–2024 | sdmx.oecd.org | 2026-10-12 |
| World Bank Open Data | Modelled estimate | 51 | 2 | 2000–2025 | api.worldbank.org | 2026-10-12 |
| ForeignAssistance.gov | Expenditure account | 50 | 5 | 2007–2026 | foreignassistance.gov | 2026-10-29 |
| WHO HIV testing services dashboard | Programme record | 40 | 5 | 2018–2024 | eic-database-290813.ew.r.appspot.com | 2026-10-14 |
| PAHO Core Indicators | Programme record | 36 | 1 | 2014–2025 | opendata.paho.org | 2026-10-13 |
| PEPFAR budgets and expenditure | Expenditure account | 31 | 8 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR testing by modality | Programme record | 30 | 6 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR Panorama Spotlight | Programme record | 30 | 8 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| Global Fund Data Service | Programme record | 29 | 5 | 2020–2025 | fetch.theglobalfund.org | 2026-10-12 |
| PAHO Interactive HIV Data Dashboard | Programme record | 22 | 2 | 2010–2025 | paho.org | 2026-10-14 |
| PEPFAR results by funding agency | Programme record | 22 | 6 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS Global AIDS Monitoring expenditure database | Expenditure account | 13 | 13 | 2022 | hivfinancial.unaids.org | 2026-10-12 |
| PEPFAR commodity procurement plans | Expenditure account | 8 | 4 | 2021–2024 | data.pepfar.gov | 2026-10-12 |
| Global Fund allocations | Expenditure account | 4 | 1 | 2017–2026 | fetch.theglobalfund.org | 2026-10-12 |
| PEPFAR human resources for health inventory | Expenditure account | 3 | 3 | 2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS Data 2025 country databook | Expenditure account | 2 | 2 | 2022 | aidsinfo.unaids.org | 2026-10-15 |
Indicators held
| Indicator | Domain | Unit | Rows | Years | Sources | Most recent value |
|---|---|---|---|---|---|---|
| Actual expenditure on collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $50k (2024) |
| Budget required for collaborative TB/HIV activities | Financing | USD | 7 | 2018–2025 | WHO Global Tuberculosis Programme | $60k (2025) |
| Country-reported HIV expenditure, all sources | Financing | USD | 5 | 2012–2022 | UNAIDS AIDSinfo, UNAIDS Global AIDS Monitoring expenditure database | $203.6m (2022) |
| Domestic funding received by the national TB programme | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $6.3m (2024) |
| Domestic public HIV expenditure | Financing | USD | 2 | 2022 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $195.4m (2022) |
| Expected Global Fund funding for the national TB programme | Financing | USD | 7 | 2018–2025 | WHO Global Tuberculosis Programme | $0 (2025) |
| Expected USAID funding for the national TB programme | Financing | USD | 7 | 2018–2025 | WHO Global Tuberculosis Programme | $0 (2025) |
| Expected domestic funding for the national TB programme | Financing | USD | 8 | 2018–2025 | WHO Global Tuberculosis Programme | $7.4m (2025) |
| Expected funding for collaborative TB/HIV activities | Financing | USD | 7 | 2018–2025 | WHO Global Tuberculosis Programme | $60k (2025) |
| External HIV financing (all donors, ODA) | Financing | USD | 22 | 2002–2024 | OECD Creditor Reporting System | $18.5m (2024) |
| External HIV financing from governments other than the United States (IATI) | Financing | USD | 26 | 2000–2025 | IATI, through d-portal | $465k (2025) |
| External HIV financing from multilateral bodies other than the Global Fund (IATI) | Financing | USD | 11 | 2012–2026 | IATI, through d-portal | $6.4m (2026) |
| External HIV financing from the United States (ODA) | Financing | USD | 34 | 2007–2026 | ForeignAssistance.gov, OECD Creditor Reporting System | $1.3m (2026) |
| Funding received for collaborative TB/HIV activities | Financing | USD | 8 | 2017–2024 | WHO Global Tuberculosis Programme | $50k (2024) |
| Global Fund HIV allocation for a whole three-year cycle, not an annual figure | Financing | USD per three-year allocation cycle | 4 | 2017–2026 | Global Fund allocations | 10,871,220 (2026) |
| Global Fund HIV disbursements to the country | Financing | USD | 39 | 2004–2026 | IATI, through d-portal, OECD Creditor Reporting System, UNAIDS Global AIDS Monitoring expenditure database | $751k (2026) |
| Global Fund funding received by the national TB programme | Financing | USD | 7 | 2017–2024 | WHO Global Tuberculosis Programme | $0 (2024) |
| HIV spending on TB/HIV co-infection | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $793k (2022) |
| HIV spending on governance and sustainability | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $1.0m (2022) |
| HIV spending on prevention | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $8.1m (2022) |
| HIV spending on prevention of vertical transmission | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $6.9m (2022) |
| HIV spending on programmes for children and adolescents | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $86 (2022) |
| HIV spending on social protection and economic support | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $8k (2022) |
| HIV spending on treatment, care and support | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $186.8m (2022) |
| International HIV expenditure (country-reported) | Financing | USD | 2 | 2022 | UNAIDS Data 2025 country databook, UNAIDS Global AIDS Monitoring expenditure database | $8.2m (2022) |
| Other bilateral HIV expenditure (country-reported) | Financing | USD | 1 | 2022 | UNAIDS Global AIDS Monitoring expenditure database | $3k (2022) |
| PEPFAR expenditure, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.9m (2025) |
| PEPFAR expenditure, USAID | Financing | USD | 3 | 2023–2025 | PEPFAR budgets and expenditure | $265k (2025) |
| PEPFAR expenditure, all US agencies | Financing | USD | 6 | 2021–2025 | PEPFAR budgets and expenditure, UNAIDS Global AIDS Monitoring expenditure database | $2.4m (2025) |
| PEPFAR expenditure, other US agencies | Financing | USD | 3 | 2021–2025 | PEPFAR budgets and expenditure | $216k (2025) |
| PEPFAR planned commodity procurement, like for like | Financing | USD | 2 | 2021–2024 | PEPFAR commodity procurement plans | $59k (2024) |
| PEPFAR planned funding (budget), all US agencies | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $3.1m (2025) |
| PEPFAR planned funding, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $2.5m (2025) |
| PEPFAR planned funding, USAID | Financing | USD | 3 | 2023–2025 | PEPFAR budgets and expenditure | $650k (2025) |
| PEPFAR planned funding, other US agencies | Financing | USD | 2 | 2021–2022 | PEPFAR budgets and expenditure | $400k (2022) |
| PEPFAR planned procurement of antiretroviral drugs | Financing | USD | 2 | 2021–2024 | PEPFAR commodity procurement plans | $0 (2024) |
| PEPFAR planned procurement of laboratory commodities | Financing | USD | 2 | 2021–2024 | PEPFAR commodity procurement plans | $0 (2024) |
| PEPFAR planned procurement of rapid test kits | Financing | USD | 2 | 2021–2024 | PEPFAR commodity procurement plans | $59k (2024) |
| PEPFAR spend on staff, human resources for health inventory | Financing | USD | 1 | 2025 | PEPFAR human resources for health inventory | $1.2m (2025) |
| PEPFAR-funded staff delivering services, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 33 (2025) |
| PEPFAR-funded staff, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 76 (2025) |
| US HIV disbursements managed by Health and Human Services | Financing | USD | 6 | 2021–2026 | ForeignAssistance.gov | $991k (2026) |
| US HIV disbursements managed by USAID | Financing | USD | 7 | 2007–2026 | ForeignAssistance.gov | $-2 (2026) |
| US HIV disbursements managed by other US agencies | Financing | USD | 16 | 2011–2026 | ForeignAssistance.gov | $0 (2026) |
| US HIV disbursements managed by the State Department | Financing | USD | 2 | 2025–2026 | ForeignAssistance.gov | $328k (2026) |
| USAID funding received by the national TB programme | Financing | USD | 7 | 2017–2024 | WHO Global Tuberculosis Programme | $0 (2024) |
| % of ALL PLHIV who are virally suppressed | Treatment cascade | percent | 23 | 2011–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory | 67.0% (2024) |
| % of PLHIV on ART (second 95, PLHIV base) | Treatment cascade | percent | 69 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory | 69.0% (2024) |
| % of PLHIV who have been diagnosed (first 95) | Treatment cascade | percent | 28 | 2011–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory | 84.0% (2024) |
| % of estimated HIV-positive incident TB cases on TB treatment and ART | Treatment cascade | percent | 18 | 2006–2024 | UNAIDS AIDSinfo | 52.9% (2024) |
| % of people currently enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 5 | 2018–2024 | UNAIDS AIDSinfo | 1.8% (2024) |
| % of people living with HIV on ART who completed a course of TB preventive therapy | Treatment cascade | percent | 4 | 2019–2024 | UNAIDS AIDSinfo | 61.6% (2024) |
| % of people newly enrolled in HIV treatment diagnosed with TB disease | Treatment cascade | percent | 9 | 2015–2024 | UNAIDS AIDSinfo | 3.9% (2024) |
| % of people newly enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 7 | 2015–2024 | UNAIDS AIDSinfo | 1.5% (2024) |
| % of people on ART who are virally suppressed (third 95) | Treatment cascade | percent | 10 | 2015–2024 | WHO Global Health Observatory | 98.0% (2024) |
| % of returned HIV test results that were positive | Treatment cascade | percent | 31 | 2018–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 1.1% (2024) |
| HIV self-test kits distributed | Treatment cascade | count | 3 | 2022–2024 | WHO HIV testing services dashboard | 11,715 (2024) |
| HIV tests performed at a health facility | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 432 (2025) |
| HIV tests performed through community outreach | Treatment cascade | count | 9 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 7,891 (2025) |
| HIV tests performed with the result returned to the person | Treatment cascade | count | 43 | 2018–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 8,323 (2025) |
| HIV-exposed infants tested within two months of birth | Treatment cascade | percent | 13 | 2010–2024 | UNAIDS AIDSinfo | 44.0% (2024) |
| HIV-positive TB patients started or continued on ART | Treatment cascade | count | 15 | 2015–2024 | WHO Global Tuberculosis Programme | 1,470 (2024) |
| Key-population people tested for HIV (count over the period) | Treatment cascade | count | 12 | 2023–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| New HIV diagnoses with a CD4 count below 200 | Treatment cascade | percent | 5 | 2015–2020 | UNAIDS AIDSinfo | 35.0% (2020) |
| Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 5 | 2021–2025 | PEPFAR results by funding agency | 313 (2025) |
| Newly diagnosed at USAID-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 3 | 2023–2025 | PEPFAR results by funding agency | 87 (2025) |
| Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW) | Treatment cascade | count | 5 | 2021–2025 | PEPFAR results by funding agency | 223 (2025) |
| Newly enrolled on ART at USAID-funded partners (MER TX_NEW) | Treatment cascade | count | 2 | 2023–2024 | PEPFAR results by funding agency | 1,150 (2024) |
| Notified HIV cases, national case surveillance | Treatment cascade | count | 48 | 2010–2025 | PAHO Core Indicators, PAHO Interactive HIV Data Dashboard | 14,169 (2025) |
| Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS) | Treatment cascade | count | 10 | 2021–2025 | PEPFAR Panorama Spotlight, PEPFAR testing by modality | 400 (2025) |
| Number of PLHIV virally suppressed (VL<1000) | Treatment cascade | count | 5 | 2021–2025 | PEPFAR Panorama Spotlight | 796 (2025) |
| Number of people on ART (PEPFAR MER TX_CURR) | Treatment cascade | count | 75 | 2000–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO Global Tuberculosis Programme | 1,306 (2025) |
| PMTCT ART coverage among pregnant women with HIV | Treatment cascade | percent | 28 | 2010–2023 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset | 80.0% (2023) |
| People newly diagnosed at a health facility | Treatment cascade | count | 5 | 2021–2025 | PEPFAR testing by modality | 123 (2025) |
| People newly diagnosed through community outreach | Treatment cascade | count | 5 | 2021–2025 | PEPFAR testing by modality | 277 (2025) |
| People newly enrolled on ART during the year | Treatment cascade | count | 18 | 2015–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme | 223 (2025) |
| People on ART at HHS/CDC-funded partners (MER TX_CURR) | Treatment cascade | count | 5 | 2021–2025 | PEPFAR results by funding agency | 1,306 (2025) |
| People on ART at USAID-funded partners (MER TX_CURR) | Treatment cascade | count | 2 | 2023–2024 | PEPFAR results by funding agency | 3,155 (2024) |
| People on ART on a dolutegravir-based regimen | Treatment cascade | percent | 10 | 2020–2025 | PAHO Interactive HIV Data Dashboard | By population group, sex or age only, to 2025 |
| People tested for HIV in the last 12 months who received the result (household survey) | Treatment cascade | percent | 34 | 2010 | Demographic and Health Surveys | By population group, sex or age only, to 2010 |
| People who completed a course of TB preventive therapy | Treatment cascade | count | 1 | 2023 | PEPFAR Panorama Spotlight | 11 (2023) |
| Pregnant women tested for HIV in antenatal care | Treatment cascade | percent | 8 | 2015–2024 | UNAIDS AIDSinfo | 98.0% (2024) |
| Pregnant women with HIV who received ARVs for PMTCT | Treatment cascade | count | 31 | 2010–2024 | PEPFAR Panorama Spotlight, UNAIDS AIDSinfo, WHO Global Health Observatory | 1,128 (2024) |
| TB patients recorded as HIV-positive | Treatment cascade | count | 15 | 2015–2024 | WHO Global Tuberculosis Programme | 2,156 (2024) |
| TB patients with an HIV test result recorded | Treatment cascade | count | 15 | 2015–2024 | WHO Global Tuberculosis Programme | 20,040 (2024) |
| AIDS-related deaths | Epidemic estimates | count | 674 | 2000–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 2,500 (2025) |
| Deaths from TB among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 610 (2024) |
| HIV prevalence among a key population | Epidemic estimates | percent | 5 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| HIV prevalence, ages 15-49 | Epidemic estimates | percent | 50 | 2000–2024 | UNAIDS AIDSinfo, World Bank Open Data | 0.6% (2024) |
| Incident TB cases among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 2,800 (2024) |
| New HIV infections | Epidemic estimates | count | 578 | 2000–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 11,000 (2025) |
| People living with HIV | Epidemic estimates | count | 681 | 2000–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset, WHO Global Health Observatory | 240,000 (2025) |
| Condom use at last higher-risk sex (household survey) | Prevention and outreach | percent | 142 | 2000–2015 | Demographic and Health Surveys | By population group, sex or age only, to 2015 |
| Key-population members reached by prevention programmes | Prevention and outreach | percent | 1 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Male condoms distributed in a year | Prevention and outreach | count | 4 | 2019–2024 | UNAIDS AIDSinfo | 30,846,637 (2024) |
| People receiving PrEP | Prevention and outreach | count | 14 | 2021–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, UNAIDS AIDSinfo | 11,000 (2024) |
| People with comprehensive correct knowledge of HIV (household survey) | Prevention and outreach | percent | 105 | 2010–2015 | Demographic and Health Surveys | By population group, sex or age only, to 2015 |
| Estimated pregnant women with HIV needing ARVs for PMTCT | Population denominators | count | 31 | 2010–2025 | UNAIDS AIDSinfo, WHO Global Health Observatory | 810 (2025) |
| Estimated size of a key population | Population denominators | count | 5 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Total population | Population denominators | count | 26 | 2000–2025 | World Bank Open Data | 53,425,635 (2025) |
| Share of HIV-exposed infants who acquire HIV | — | percent | 30 | 2010–2025 | UNAIDS AIDSinfo, UNICEF HIV/AIDS dataset | 12.3% (2025) |
Every row shown on the Colombia page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.
Turn your phone to read the chart upright